Patient characteristics and outcome parameters
| Variable . | Induction treatment without bevacizumab (n = 85) . | Induction treatment with bevacizumab 10 mg (n = 86) . | . |
|---|---|---|---|
| Age, y | (P = .077, K-W) | ||
| Mean | 67 | 68 | |
| Range | 61-80 | 61-78 | |
| Median | 65 | 67 | |
| Age subgroup, y, n (%) | (P = .042, χ2)* | ||
| 60-64 | 37 (44%) | 22 (26%) | |
| 65-70 | 30 (35%) | 43 (50%) | |
| > 70 | 18 (21%) | 21 (24%) | |
| Male sex, n (%) | 46 (54%) | 48 (56%) | (P = .824, χ2) |
| MDS, n (%) | 11 (13%) | 14 (17%) | (P = .538, χ2) |
| Secondary AML, n (%) | 10 (12%) | 12 (14%) | (P = .670, χ2) |
| WHO performance score, n (%) | (P = .634, FE) | ||
| 0 | 41 (48%) | 43 (50%) | |
| 1 | 37 (44%) | 36 (42%) | |
| 2 | 7 (8%) | 5 (6%) | |
| WBC at diagnosis, n (%) | (P = .555, χ2) | ||
| Mean (range) | 20 (0.9-194) | 27 (0.5-236) | |
| < 20 × 109/L | 65 (76%) | 62 (72%) | |
| > 20-100 × 109/L | 16 (19%) | 16 (19%) | |
| > 100 × 109/L | 4 (5%) | 8 (9%) | |
| Cytogenetic risk, n (%) | (P = .610, FE) | ||
| Favorable | 4 (5%) | 2 (2%) | |
| Intermediate | 43 (51%) | 42 (49%) | |
| Unfavorable | 20 (24%) | 28 (33%) | |
| Very unfavorable | 14 (16%) | 11 (13%) | |
| No cytogenetics available | 4 (5%) | 3 (3%) | |
| Cycle 2 given, n (%) | 63 (74%) | 66 (79%) | (P = .497, χ2) |
| Response after 24 mo, n (%) | |||
| CR | 56 (65%) | 56 (65%) | (P = .916, FE) |
| CR, cycle 1 | 42 (75%) | 41 (73%) | (P = .831, FE) |
| CR, cycle 2 | 14 (25%) | 15 (27%) | |
| Relapse | 32 (38%) | 36 (42%) | (P = .726, FE) |
| Died | 61 (72%) | 61 (71%) | |
| Died in CR | 4 (5%) | 6 (7%) | |
| Variable . | Induction treatment without bevacizumab (n = 85) . | Induction treatment with bevacizumab 10 mg (n = 86) . | . |
|---|---|---|---|
| Age, y | (P = .077, K-W) | ||
| Mean | 67 | 68 | |
| Range | 61-80 | 61-78 | |
| Median | 65 | 67 | |
| Age subgroup, y, n (%) | (P = .042, χ2)* | ||
| 60-64 | 37 (44%) | 22 (26%) | |
| 65-70 | 30 (35%) | 43 (50%) | |
| > 70 | 18 (21%) | 21 (24%) | |
| Male sex, n (%) | 46 (54%) | 48 (56%) | (P = .824, χ2) |
| MDS, n (%) | 11 (13%) | 14 (17%) | (P = .538, χ2) |
| Secondary AML, n (%) | 10 (12%) | 12 (14%) | (P = .670, χ2) |
| WHO performance score, n (%) | (P = .634, FE) | ||
| 0 | 41 (48%) | 43 (50%) | |
| 1 | 37 (44%) | 36 (42%) | |
| 2 | 7 (8%) | 5 (6%) | |
| WBC at diagnosis, n (%) | (P = .555, χ2) | ||
| Mean (range) | 20 (0.9-194) | 27 (0.5-236) | |
| < 20 × 109/L | 65 (76%) | 62 (72%) | |
| > 20-100 × 109/L | 16 (19%) | 16 (19%) | |
| > 100 × 109/L | 4 (5%) | 8 (9%) | |
| Cytogenetic risk, n (%) | (P = .610, FE) | ||
| Favorable | 4 (5%) | 2 (2%) | |
| Intermediate | 43 (51%) | 42 (49%) | |
| Unfavorable | 20 (24%) | 28 (33%) | |
| Very unfavorable | 14 (16%) | 11 (13%) | |
| No cytogenetics available | 4 (5%) | 3 (3%) | |
| Cycle 2 given, n (%) | 63 (74%) | 66 (79%) | (P = .497, χ2) |
| Response after 24 mo, n (%) | |||
| CR | 56 (65%) | 56 (65%) | (P = .916, FE) |
| CR, cycle 1 | 42 (75%) | 41 (73%) | (P = .831, FE) |
| CR, cycle 2 | 14 (25%) | 15 (27%) | |
| Relapse | 32 (38%) | 36 (42%) | (P = .726, FE) |
| Died | 61 (72%) | 61 (71%) | |
| Died in CR | 4 (5%) | 6 (7%) | |
MDS indicates myelodysplastic syndrome; K-W, Kruskal-Wallis; FE, Fisher exact test; WHO, World Health Organization; and WBC, white blood cell.
Multivariate analysis including age group and treatment showed that age group did not influence the end points of this study.